| Width2: | 175 |
| Tradename: | Incruse Ellipta |
| Dailymedid: | Umeclidinium bromide |
| Routes Of Administration: | Inhalation (DPI) |
| Atc Prefix: | R03 |
| Atc Suffix: | BB07 |
| Atc Supplemental: | (+vilanterol) |
| Legal Au: | S4 |
| Legal Au Comment: | [1] |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [2] |
| Legal Uk: | POM |
| Legal Us: | Rx-only |
| Legal Status: | Rx-only |
| Protein Bound: | ~89%[3] |
| Metabolism: | Liver (CYP2D6) |
| Elimination Half-Life: | 11 hours |
| Excretion: | Feces (58%) and urine (22%) |
| Cas Number: | 869113-09-7 |
| Pubchem: | 11519069 |
| Chemspiderid: | 9693857 |
| Unii: | 7AN603V4JV |
| Kegg: | D10181 |
| Chebi: | 79040 |
| Synonyms: | GSK573719A |
| Iupac Name: | Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide |
| C: | 29 |
| H: | 34 |
| Br: | 1 |
| N: | 1 |
| O: | 2 |
| Stdinchi: | 1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 |
| Stdinchikey: | PEJHHXHHNGORMP-UHFFFAOYSA-M |
| Smiles: | OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-] |
Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[4] [5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[6]
It is on the World Health Organization's List of Essential Medicines.[7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1million prescriptions.[8] [9]